Danegaptide
Also known as: Danegaptide, Danegaptide hydrochloride, Gap junction antiarrhythmic peptide analog, GAP‑134, ZP1609
Source Danegaptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Danegaptide (also known as GAP‑134) is a synthetic hexapeptide investigated for cardioprotective and renoprotective effects by targeting connexin43 hemichannels. It has been studied in phase II trials for myocardial infarction and acute kidney injury but is not approved for clinical use.
Mechanism of Action
Selective modulation of connexin43 hemichannels, reducing pathological intercellular signaling during ischemia-reperfusion and attenuating cell death pathways
Routes of Administration
Goals & Uses
- Prevention of ischemia-reperfusion injuryCardioprotection / CytoprotectionModerate
- Antiarrhythmic effect during reperfusionArrhythmia PreventionLow
- Renal protection in acute kidney injuryRenalModerate
- Cardioprotection after myocardial infarctionCardiovascularModerate
- Reduction of myocardial infarct sizeCardioprotectionModerate
- Improvement of cardiac conductionElectrophysiologyLow
Contraindications
- Known hypersensitivity to Danegaptide or its excipientsAllergyHigh
- Severe pre-existing arrhythmia not related to ischemiaCardiacModerate
- Known hypersensitivity to danegaptide or excipientsAllergyHigh
Adverse Effects
- Injection site reactionsLocalUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- Infusion site erythemaLocalCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- BradycardiaCardiovascularRare
Drug Interactions
- Concurrent use with other connexin modulatorsModerate
- Antiarrhythmic agents (Class I/III)Moderate
- Thrombolytics / antiplatelet agentsLow
Population Constraints
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorisation only.
- United StatesInvestigationalInvestigational New Drug (IND) status; no approved indication.
- United KingdomInvestigationalSubject to MHRA clinical trial approval.
No FDA or EMA approval; used only within clinical trial protocols.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Danegaptide?
Danegaptide (also known as GAP‑134) is a synthetic hexapeptide investigated for cardioprotective and renoprotective effects by targeting connexin43 hemichannels. It has been studied in phase II trials for myocardial infarction and acute kidney injury but is not approved for clinical use.
What is Danegaptide used for?
Danegaptide is educationally associated with: Prevention of ischemia-reperfusion injury, Antiarrhythmic effect during reperfusion, Renal protection in acute kidney injury, Cardioprotection after myocardial infarction, Reduction of myocardial infarct size, Improvement of cardiac conduction. Educational only — not medical advice.
How is Danegaptide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Danegaptide?
Reported adverse effects include: Injection site reactions, Hypotension, Infusion site erythema, Nausea, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Danegaptide?
Recorded contraindications: Known hypersensitivity to Danegaptide or its excipients, Severe pre-existing arrhythmia not related to ischemia, Known hypersensitivity to danegaptide or excipients. Consult a qualified clinician before use.